Literature DB >> 9602953

Balanced designs in longitudinal population pharmacokinetic studies.

E I Ette1, H Sun, T M Ludden.   

Abstract

A simulation study was performed using a balanced design to determine the sample size required for accurate and precise estimation of a parameter at a given level of intersubject variability in a longitudinal population pharmacokinetic study. A two-compartment model parameterized in terms of clearance (Cl), volumes of the central (V1) and peripheral (V2) compartments, and intercompartmental clearance (Q) with multiple intravenous bolus inputs was assumed. Six samples were obtained from each subject using the informative profile (block) randomized design. Variability (in terms of coefficient of variation, CV) in model parameters was varied between 30% and 100%, and residual variability was fixed at 15%. Sample sizes ranging from 30 to 1,000 subjects were studied, and a hundred replicate data sets were generated and analyzed with NONMEM for each sample size at each CV. A sample size of 30 was required for accurate and precise estimation of structural model parameters when CV < or = 75%, except for Cl where it is adequate for CV < or = 100%. A sample size of 80 was required for intersubject variability estimation with CV < or = 60%. Robust estimates of variability in Cl were obtained with sample sizes of 30 (CV < or = 45%), 60 (CV 60-75%), and 100 (CV > or = 75%). Positively biased estimates of residual variability were obtained irrespective of sample size at > or = 60% CV. This indicates that estimates of residual variability obtained in study situations where CV > or = 60% should be interpreted with caution. In such situations model misspecification may not be the issue, because in this simulation study concentration-time profiles were generated and analyzed with the same model. Although these results should be interpreted within the context of the study, they provide a framework for addressing the issue of sample size in longitudinal population pharmacokinetic study with a balanced sampling design. The result of a population pharmacokinetic study can be anticipated by comparing the results of several simulations in which the various input factors have been varied.

Mesh:

Year:  1998        PMID: 9602953     DOI: 10.1002/j.1552-4604.1998.tb04446.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

3.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 4.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 5.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 6.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

7.  Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.

Authors:  Ali-Akbar Golabchifar; Saeed Rezaee; Nahid Mobarghei Dinan; Abbas Kebriaeezadeh; Mohammad-Reza Rouini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

8.  Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery.

Authors:  Athena F Zuppa; Susan C Nicolson; Jeffrey S Barrett; Marc R Gastonguay
Journal:  J Pediatr       Date:  2011-06-12       Impact factor: 4.406

Review 9.  The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.

Authors:  P J Williams; E I Ette
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

10.  Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Authors:  Bruce Green; Herta Crauwels; Thomas N Kakuda; Simon Vanveggel; Anne Brochot
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.